Key result
Sympathetic overdrive and elevated resting heart rate worsen the prognosis in coronary heart disease, while beta-blockers like bisoprolol effectively control symptoms and improve long-term outcomes.
Why the study?
Do beta-blockers (bisoprolol) improve prognosis and control symptoms in patients with coronary heart disease and sympathetic overdrive?
Do beta-blockers (bisoprolol) improve prognosis and control symptoms in patients with coronary heart disease and sympathetic overdrive?
This review highlights the importance of controlling sympathetic overdrive and elevated resting heart rate in coronary heart disease using beta-blockers like bisoprolol to improve patient outcomes.
Answers are grounded in this paper and cite their sources.
Supports sympathetic overdrive control with bisoprolol in CHD; leaves open prospective RCTs to confirm prognostic benefit.
Sympathetic overdrive (sympathetic hyperactivation) plays a key role in the pathogenesis of coronary heart disease and its adverse outcomes. An increased heart rate at rest as a manifestation of hyperactivation of the sympathetic nervous system is a factor worsening the prognosis in patients with ischemic heart disease.Beta-blockers are recognized as first-line drugs for controlling symptoms in coronary heart disease with a proven effect on prognosis. Bisoprolol is a β1-selective beta-blocker with high antianginal and prognostic modulating efficacy.
No takes yet. Share an insight, caveat, or question.
N. V. Schepinа (2020) conducted a review in Coronary heart disease. Beta-blockers (Bisoprolol) was evaluated. Sympathetic overdrive and elevated resting heart rate worsen the prognosis in coronary heart disease, while beta-blockers like bisoprolol effectively control symptoms and improve long-term outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: